iAtoday
Group Benefits
and Retirement Solutions
Are your clients concerned about rising drug plan costs and looking for better ways to manage them? That’s understandable given that from 2021 to 2025, the cost per plan member in Canada’s private prescription drug plans rose by 32.5%.1
When it comes to prescription drugs, cost management raises a number of challenges: how can costs be controlled without compromising access to treatment or adversely affecting people’s health? Which indicators can help distinguish spending that truly creates value from spending that delivers less?
Our article Prescription drugs: Turning an expense into an investment builds on the findings presented in our white paper to explain why the cost of a drug alone is not enough to assess a plan’s performance. It is equally important to consider the broader benefits it delivers, including a person’s health, their ability to work and their productivity.
“Drugs are among the most effective healthcare investments for organizations. When they are appropriate, accessible and used as intended, they support the total wellbeing of both individuals and their workplace.”
Erika Hatherly, Strategic Leader, Drug Programs
What rising costs don’t show us
Although controlling costs is important, those costs do not reflect all the positive outcomes a treatment can deliver. A claim may be submitted for a treatment that helps an individual better manage their condition and continue working productively, something that might not be possible if they did not have access to that treatment. While the expense is easy to quantify, the actual benefits are often much harder to measure.
Organizations therefore need to distinguish between spending that truly improves workforce health and spending that creates less value.
“Responsible cost management and improved health outcomes go hand in hand. The best decisions help ensure each person receives the right treatment at the right time.”
Frédéric Leblanc, Strategic Lead, Products and Drugs Programs
Our article takes a closer look at these issues and outlines strategies for balancing access to treatment with the long-term viability of the plan. This will help you guide your discussions with plan sponsors and maximize the strategic value of your advisory role.
|
Insights: Inform and inspire Trends, issues, viewpoints, diverse and innovative solutions: content that combines our know-how with a visionary perspective to better understand the evolution of the industry and inspire action. |
1 Express Scripts Canada, annual industry data covering the period 2021–2025
Also in this issue
- Study | Medical leave: beyond coverage
- Digital experience | iA Mobile continues to evolve
- Quarterly Update | September 30 edition available
- Asset Management | Jarislowsky Fraser announces two appointments to its Canadian Equity team
- Appointments | Two new additions to the Group Insurance team
- Paramedical care | Reasonable and customary fees 2027
